(NYSE: NVO) Novo Nordisk A S's forecast annual revenue growth rate of 21.03% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.32%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.27%.
Novo Nordisk A S's revenue in 2024 is $33,808,005,822.On average, 2 Wall Street analysts forecast NVO's revenue for 2024 to be $189,438,049,020,000, with the lowest NVO revenue forecast at $184,732,351,100,000, and the highest NVO revenue forecast at $194,143,751,450,000. On average, 3 Wall Street analysts forecast NVO's revenue for 2025 to be $233,934,583,960,000, with the lowest NVO revenue forecast at $228,680,632,400,000, and the highest NVO revenue forecast at $236,609,798,700,000.
In 2026, NVO is forecast to generate $268,067,833,440,000 in revenue, with the lowest revenue forecast at $260,647,061,400,000 and the highest revenue forecast at $275,488,605,480,000.